USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CORAMED TECHNOLOGIES
Address:
6225 W HOWARD ST
NILES, IL
Phone:
N/A
URL:
N/A
EIN:
126152929
DUNS:
809247880
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $113,564.00 1
SBIR Phase II $3,985,485.00 2

Award List:

Development of New-Generation Thrombelastograph (R)

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$113,564.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Nearly 2 million people are hospitalized each year for ischemic events. To minimize the risk of recurrent events, nearly all patients are prescribed aspirin or other antiplatelet therapy and 86% are prescribed anticoagu lants upon discharge. Anticoagulation and… More

Development of next-generation Thrombelastographs

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,027,275.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Coramed is designing a next-generation point-of-care (POC) instrument, the TEG 6500, for monitoring patient hemostasis on demand. The instrument will introduce a completely new technology for monitoring clot formation a nd breakdown that is well suited for the… More

Development of next-generation Thrombelastographs

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$2,958,210.00
Agency:
HHS
Principal Investigator:
Gabriel Raviv – 847-647-8800
Abstract:
DESCRIPTION (provided by applicant): Coramed is commercializing next-generation point of care instruments, the TEG 6000 series, for monitoring patient hemostasis on demand. This project includes activities to take the technology from the prototype stage completed in Phase II to FDA-cleared and… More